Comparison of High-Dose Dexamethasone and Prednisone for Initial Treatment of Adult
Primary Immune Thrombocytopenia
Copyright © 2012 SciRes. OJBD
89
[5] J. N. George, S. H. Woolf, G. E. Raskob, J. S. Wasser, L.
M. Aledort, P. J. Ballem, et al., “Idiopathic Thrombocy-
topenic Purpura: A Practice Guideline Developed by Ex-
plicit Methods for the American Society of Hematol-
ogy,” Blood, Vol. 88, No. 1, 1996, pp. 3-40.
[6] M. G. Mazzucconi, M. Francesconi, P. Fidani, G. Di
Nucci, G. M. Gandolfo, A. Afeltra, et al., “Treatment of
Idiopathic Thrombocytopenic Purpura (ITP): Results of a
Multicentric Protocol,” Haematologica, Vol. 70, No. 4,
1985, pp. 329-336.
[7] J. E. Portielje, R. G. Westendorp, H. C. Kluin-Nelemans
and A. Brand, “Morbidity and Mortality in Adults with
Idiopathic Thrombocytopenic Purpura,” Blood, Vol. 97,
No. 9, 2001, pp. 2549-2554.
doi:10.1182/blood.V97.9.2549
[8] J. C. Andersen, “Response of Resistant Idiopathic Throm-
bocytopenic Purpura to Pulsed High-Dose Dexametha-
sone Therapy,” New England Journal of Medicine, Vol.
330, No. 22, 1994, pp. 1560-1564.
doi:10.1056/NEJM199406023302203
[9] I. Khouri, B. Tuan and K. Grant, “Comment on: Immune
Thrombocytopenic Purpura,” New England Journal of
Medicine, Vol. 347, No. 6, 2002, pp. 449-450.
doi:10.1056/NEJM200208083470617
[10] M. Warner, P. Wasi, S. Couban, C. Hayward, T. Warken-
tin and J. D. Kelton, “Failure of Pulse High-Dose Dexa-
methasone in Chronic Idiopathic Immune Thrombocyto-
penia,” American Journal of Hematology, Vol. 54, No. 4,
1997, pp. 267-270.
doi:10.1002/(SICI)1096-8652(199704)54:4<267::AID-AJ
H1>3.0.CO;2-T
[11] Y. Cheng, R. S. Wong, Y. O. Soo, C. H. Chui, F. Y. Lau,
N. P. Chan, et al., “Initial Treatment of Immune Throm-
bocytopenic Purpura with High-Dose Dexamethasone,”
New England Journal of Medicine, Vol. 349, No. 9, 2003,
pp. 831-836. doi:10.1056/NEJMoa030254
[12] F. Borst, J. J. Keuning, H. van Hulsteijn, H. Sinnige and
G. Vreugdenhil, “High-Dose dexamethasone as a First-
and Second-Line Treatment of Idiopathic Thrombocyto-
penic Purpura in Adults,” Annals of Hematology, Vol. 83,
No. 12, 2004, pp. 764-768.
doi:10.1007/s00277-004-0908-1
[13] M. G. Mazzucconi, P. Fazi, S. Bernasconi, G. De Rossi,
G. Leone, L. Gugliotta, et al., “Therapy with High-Dose
Dexamethasone (HD-DXM) in Previously Untreated Pa-
tients Affected by Idiopathic Thrombocytopenic Purpura:
A GIMEMA Experience,” Blood, Vol. 109, No. 4, 2007,
pp. 1401-1407. doi:10.1182/blood-2005-12-015222
[14] E. L. Kaplan and P. Meier, “Nonparametric Estimation
from Incomplete Observations,” Journal of the American
Statistical Association, Vol. 53, No. 282, 1958, pp. 457-
481. doi:10.2307/2281868
[15] C. Guo, X. Chu, Y. Shi, W. He, L. Li, L. Wang, et al.,
“Correction of Th1-Dominant Cytokine Profiles by High-
Dose Dexamethasone in Patients with Chronic Idiopathic
Thrombocytopenic Purpura,” Journal of Clinical Immu-
nology, Vol. 27, No. 6, 2007, pp. 557-562.
doi:10.1007/s10875-007-9111-1
[16] N. N. Shan, X. J. Zhu, Q. Wang, C. Y. Wang, P. Qin, J.
Peng, et al., “High-Dose Dexamethasone Regulates Inter-
leukin-18 and Interleukin-18 Binding Protein in Idio-
pathic Thrombocytopenic Purpura,” Haematologica, Vol.
94, No. 11, pp. 1603-1607.
doi:10.3324/haematol.2009.007708
[17] X. G. Liu, S. H. Ma, J. Z. Sun, J. Ren, Y. Shi, L. Sun, et
al., “High-Dose Dexamethasone Shifts the Balance of Sti-
mulatory and Inhibitory Fcgamma Receptors on Mono-
cytes in Patients with Primary Immune Thrombocyto-
penia,” Blood, Vol. 117, No. 6, 2011, pp. 2061-2069.
doi:10.1182/blood-2010-07-295477
[18] X. X. Chu, B. H. Huang, X. L. Zhang, L. M. Chen, Y.
Wang, W. L. Yu, et al., “Dexamethasone Inhibits Immu-
noreactivity of Dendritic Cells in Patients with Chronic
Idiopathic Thrombocytopenic Purpura,” Blood Coagula-
tion & Fibrinolysis, Vol. 21, No. 6, 2010, pp. 564-567.
doi:10.1097/MBC.0b013e32833c2b8c
[19] X. J. Zhu, Y. Shi, J. Z. Sun, N. N. Shan, J. Peng, C. S.
Guo, et al., “High-Dose Dexamethasone Inhibits BAFF
Expression in Patients with Immune Thrombocytopenia,”
Journal of Clinical Immunology, Vol. 29, No. 5, 2009, pp.
603-610. doi:10.1007/s10875-009-9303-y
[20] Y. Ling, X. Cao, Z. Yu and C. Ruan, “Circulating Den-
dritic Cells Subsets and CD4+ Foxp3+ Regulatory T-
Cells in Adult Patients with Chronic ITP before and after
Treatment with High-Dose Dexamethasome,” European
Journal of Haematology, Vol. 79, No. 4, 2007, pp. 310-
316. doi:10.1111/j.1600-0609.2007.00917.x
[21] F. Zaja, M. Baccarani, P. Mazza, M. Bocchia, L. Gugli-
otta, A. Zaccaria et al., “Dexamethasone plus Rituximab
Yields Higher Sustained Response Rates than Dexame-
thasone Monotherapy in Adults with Primary Immune
Thrombocytopenia,” Blood, Vol. 115, No. 14, 2010, pp.
2755-2762. doi:10.1182/blood-2009-07-229815
[22] K. Fujimura, M. Kuwana, Y. Kurata, M. Imamura, H.
Harada, H. Sakamaki, et al., “Is Eradication Therapy Use-
ful as the First Line of Treatment in Helicobacter Py-
lori-Positive Idiopathic Thrombocytopenic Purpura? Ana-
lysis of 207 Eradicated Chronic ITP Cases in Japan,” In-
ternational Journal of Hematology, Vol. 81, No. 2, 2005,
pp. 162-168. doi:10.1532/IJH97.04